Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting that it can dose its genetic therapy monthly.
Paul Bolno, Wave Life Sciences CEO
May 19, 2026 11:19 AM EDT
Wave aims for monthly dosing with RNA editing treatment for AATD
Lei Lei Wu
News Reporter
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering…
Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections,…
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR…
MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according…
NYT: A new drug for a subset of patients 'tells us that ALS is treatable', expert says.
After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis’ antisense oligonucleotide Wainua (eplontersen), the…
